Potential New Severe Asthma Biologic
Trial Objectives
Severe asthma can involve airway inflammation driven by specific immune molecules. Researchers are studying an investigational medication called WIN378 to see if it can help adults with severe asthma better control their symptoms and reduce asthma attacks by blocking these molecules.In this study, volunteers will be randomly assigned to receive either WIN378 or a placebo (a medication with no active ingredient). At clinic visits, they will undergo physical exams and spirometry tests, receive an electrocardiogram (ECG), and provide blood samples. Data collected will help researchers determine if this new treatment is safe, effective and can help improve quality of life.
Who Can Participate
People 18-75 years old who have been diagnosed with severe asthma with a T2-high phenotype.
Age: 18-75 Gender: Any
Estimated Time Commitment
Up to 14 visits up to over 113 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Windward Bio AG
Principal Investigators
Michael E. Wechsler, MD, MMSc